Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19
Go back to Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19| iShares Diversified Alternatives Trust (NASDAQ: ALT) | Delayed: 2.91 -0.02 (0.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.93 | 52 Week High | $54.24 | |||
| Open | $2.88 | 52 Week Low | $48.35 | |||
| Day High | $3.04 | P/E | N/A | |||
| Day Low | $2.88 | EPS | $0.00 | |||
| Volume | 4,216,865 | |||||
